CAB Spotlight - Vijaya Jori | Johns Hopkins University Baltimore-India Clinical Trials Unit

CAB Spotlight - Vijaya Jori

Date: 04/01/2022

Community Advisory Boards are key members of research programs. The ACTG Newsletter features Vijaya Jori of the JHU-BJGMC CAB!

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Study Description A5384 is a trial for people who have or might have tuberculous meningitis (TBM). TBM is an infectious disease...

Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...